Drug intelligence / Profile preview

SER-227

Development stage: Preclinical
Lead developer: Serina Therapeutics
Modality: Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

SER-227 is a small molecule central nervous system (CNS) drug candidate developed by Serina Therapeutics. It leverages the company's proprietary POZ polymer conjugate platform to potentially treat Parkinson's disease. The drug is part of Serina's clinical pipeline, which the company aims to advance into clinical trials following its reverse merger with AgeX Therapeutics.

Targets

DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on SER-227.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SER-227.